Difference between revisions of "Inherited coagulopathy"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "*<big>We have moved How I Treat articles to a dedicated page.</big>" to "*''We have moved How I Treat articles to a dedicated page.''") |
||
(55 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <span id="BackToTop"></span> | |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
− | + | {{#lst:Editorial board transclusions|heme}} | |
− | + | *''We have moved [[How I Treat]] articles to a dedicated page.'' | |
− | |||
− | |||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
− | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> |
− | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] | + | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> |
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
+ | =Guidelines= | ||
+ | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
+ | ==ASH/ISTH/NHF/WFH== | ||
+ | *'''2021:''' James et al. [https://doi.org/10.1182/bloodadvances.2020003265 ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease] [https://www.ncbi.nlm.nih.gov/pubmed/33570651 PubMed] | ||
+ | *'''2021:''' Connell et al. [https://doi.org/10.1182/bloodadvances.2020003264 ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease] [https://www.ncbi.nlm.nih.gov/pubmed/33570647 PubMed] | ||
+ | |||
+ | ==BSH== | ||
+ | *'''2020:''' Rayment et al. [https://doi.org/10.1111/bjh.16704 Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B] [https://www.ncbi.nlm.nih.gov/pubmed/32390158 PubMed] | ||
=Factor VIII deficiency (Hemophilia A), replacement products= | =Factor VIII deficiency (Hemophilia A), replacement products= | ||
To be completed | To be completed | ||
+ | =Factor VIII deficiency (Hemophilia A), without inhibitors, all lines of therapy= | ||
+ | ==Emicizumab monotherapy {{#subobject:c1a40e|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Regimen {{#subobject:cfdeed|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 25%"|Study | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|Comparator | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1056/NEJMoa1803550 Mahlangu et al. 2018 (HAVEN 3)] | ||
+ | |style="background-color:#1a9851"|Phase 3 (E-esc) | ||
+ | |[[#Observation_888|No prophylaxis]] | ||
+ | |style="background-color:#1a9850"|Lower bleeding rate (primary endpoint) | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/S2352-3026(22)00377-5 Negrier et al. 2023 (HAVEN 6)] | ||
+ | | style="background-color:#91cf61" |Non-randomized phase 3 | ||
+ | | style="background-color:#d3d3d3" | | ||
+ | | style="background-color:#d3d3d3" | | ||
+ | |- | ||
+ | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Supportive therapy==== | ||
+ | *[[Emicizumab (Hemlibra)]] | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | # '''HAVEN 3:''' Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. [https://doi.org/10.1056/NEJMoa1803550 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30157389/ PubMed] [https://clinicaltrials.gov/study/NCT02847637 NCT02847637] | ||
+ | #'''HAVEN 6:''' Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jimenez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar;10(3):e168-e177. Epub 2023 Jan 27. [https://doi.org/10.1016/S2352-3026(22)00377-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36716761/ PubMed] [https://clinicaltrials.gov/study/NCT04158648 NCT04158648] | ||
=Factor VIII deficiency (Hemophilia A), with inhibitors, all lines of therapy= | =Factor VIII deficiency (Hemophilia A), with inhibitors, all lines of therapy= | ||
==Emicizumab monotherapy {{#subobject:f198c0|Regimen=1}}== | ==Emicizumab monotherapy {{#subobject:f198c0|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:cbc686|Variant=1}}=== | ===Regimen {{#subobject:cbc686|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | !Study | + | !style="width: 25%"|Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
− | !Comparator | + | !style="width: 25%"|Comparator |
− | ![[Levels_of_Evidence# | + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
− | |[ | + | |[https://doi.org/10.1056/NEJMoa1703068 Oldenburg et al. 2017 (HAVEN 1)] |
− | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (E-esc) |
− | |No prophylaxis | + | |[[#Observation_888|No prophylaxis]] |
− | |style="background-color:#1a9850"|Lower bleeding rate | + | |style="background-color:#1a9850"|Lower bleeding rate (primary endpoint) |
|- | |- | ||
|} | |} | ||
− | + | <div class="toccolours" style="background-color:#b3e2cd"> | |
− | ==== | + | ====Supportive therapy==== |
− | *[[Emicizumab | + | *[[Emicizumab (Hemlibra)]] |
− | + | </div></div> | |
===References=== | ===References=== | ||
− | # '''HAVEN 1:''' Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. [ | + | # '''HAVEN 1:''' Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. [https://doi.org/10.1056/NEJMoa1703068 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28691557/ PubMed] |
− | + | # '''HAVEN 2:''' Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12;134(24):2127-2138. [https://doi.org/10.1182/blood.2019001869 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31697801/ PubMed] | |
==Rituximab monotherapy {{#subobject:6d79c2|Regimen=1}}== | ==Rituximab monotherapy {{#subobject:6d79c2|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:3f9925|Variant=1}}=== | ===Regimen {{#subobject:3f9925|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !Study | + | !style="width: 33%"|Study |
− | ![[Levels_of_Evidence#Evidence|Evidence]] | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5726888/ Leissinger et al. 2014 (RICH)] |
− | |style="background-color:#91cf61"|Phase | + | |2006-08 to 2010-11 |
+ | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Immunosuppressive therapy==== | ====Immunosuppressive therapy==== | ||
− | *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once | + | *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 |
− | + | '''7-day cycle for 4 cycles (28-day course)''' | |
− | '''28-day course''' | + | </div></div> |
− | |||
===References=== | ===References=== | ||
− | # Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep;87(9):933-6. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645919/ link to PMC article] '''does not contain | + | # Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep;87(9):933-6. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645919/ link to PMC article] '''does not contain dosing details''' [https://pubmed.ncbi.nlm.nih.gov/22733686/ PubMed] |
− | # Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014 Sep 2;112(3):445-58. [ | + | # '''RICH:''' Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014 Sep 2;112(3):445-58. Epub 2014 Jun 12. [https://doi.org/10.1160/TH14-01-0078 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5726888/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/24919980/ PubMed] [https://clinicaltrials.gov/study/NCT00331006 NCT00331006] |
=Factor IX deficiency (Hemophilia B), all lines of therapy= | =Factor IX deficiency (Hemophilia B), all lines of therapy= | ||
To be completed | To be completed | ||
− | |||
[[Category:Inherited coagulopathy regimens]] | [[Category:Inherited coagulopathy regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Bleeding disorders]] | [[Category:Bleeding disorders]] |
Latest revision as of 11:34, 15 May 2024
Section editor | |
---|---|
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
- We have moved How I Treat articles to a dedicated page.
3 regimens on this page
3 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ASH/ISTH/NHF/WFH
- 2021: James et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease PubMed
- 2021: Connell et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease PubMed
BSH
- 2020: Rayment et al. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B PubMed
Factor VIII deficiency (Hemophilia A), replacement products
To be completed
Factor VIII deficiency (Hemophilia A), without inhibitors, all lines of therapy
Emicizumab monotherapy
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Mahlangu et al. 2018 (HAVEN 3) | Phase 3 (E-esc) | No prophylaxis | Lower bleeding rate (primary endpoint) |
Negrier et al. 2023 (HAVEN 6) | Non-randomized phase 3 |
Supportive therapy
References
- HAVEN 3: Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. link to original article PubMed NCT02847637
- HAVEN 6: Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jimenez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar;10(3):e168-e177. Epub 2023 Jan 27. link to original article PubMed NCT04158648
Factor VIII deficiency (Hemophilia A), with inhibitors, all lines of therapy
Emicizumab monotherapy
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Oldenburg et al. 2017 (HAVEN 1) | Phase 3 (E-esc) | No prophylaxis | Lower bleeding rate (primary endpoint) |
Supportive therapy
References
- HAVEN 1: Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818. Epub 2017 Jul 10. link to original article PubMed
- HAVEN 2: Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 Dec 12;134(24):2127-2138. link to original article PubMed
Rituximab monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Leissinger et al. 2014 (RICH) | 2006-08 to 2010-11 | Phase 2 |
Immunosuppressive therapy
- Rituximab (Rituxan) 375 mg/m2 IV once on day 1
7-day cycle for 4 cycles (28-day course)
References
- Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep;87(9):933-6. link to PMC article does not contain dosing details PubMed
- RICH: Leissinger C, Josephson CD, Granger S, Konkle BA, Kruse-Jarres R, Ragni MV, Journeycake JM, Valentino L, Key NS, Gill JC, McCrae KR, Neufeld EJ, Manno C, Raffini L, Saxena K, Torres M, Marder V, Bennett CM, Assmann SF. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Haemost. 2014 Sep 2;112(3):445-58. Epub 2014 Jun 12. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00331006
Factor IX deficiency (Hemophilia B), all lines of therapy
To be completed